Large pooled analysis reveals prognostic utility of circulating tumour cells in MM

A large study on circulating tumour cells (CTCs) in patients with previously untreated multiple myeloma (MM) demonstrated their prognostic utility for progression-free survival (PFS), even when other factors, such as cytogenetics and the International Staging System, were taken into account. “Since there is no consensus on how to stratify patients with MM based on CTCs, we performed an analysis among 2,466 patients with newly diagnosed MM to investigate this matter,” said Dr Luca Bertamini (University of Turin, Italy) [1]. The study comprised a diverse population: 45% of the patients were 65 years or older, 48% were ineligible for transplant, and 59% participated in clinical trials. After a median follow-up of 56.8 months, the median CTC level was 0.017%, with no observed differences between the datasets from the 6 participating European countries. Dr Bertamini highlighted that continuous CTC levels were prognostic of PFS outcomes. “We were able to...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 June 20252 September 2025